0443 GMT - Pro Medicus has never been better positioned despite its recent share-price dive, Morgans analyst Iain Wilkie reckons. Shares in the medical-imaging tech provider shed two-thirds of their value between July and February. However, Wilkie tells clients in a note that conversations with the company and industry contacts have reinforced his view that the business is executing well from a structurally strong competitive position. With consensus forecasts now reflecting lower expectations, he keeps a buy rating and target price of 210.00 Australian dollars on the stock. Shares are up 0.3% at A$160.495. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 03, 2026 00:43 ET (04:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.